Pharmaceutical

Shionogi secures licence for Maze’s Pompe disease treatment

Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’ MZE001 aimed at treating Pompe disease.

May 11, 2024 - 04:00
Shionogi secures licence for Maze’s Pompe disease treatment
Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’ MZE001 aimed at treating Pompe disease.
Read the original article

Tags:

Previous Article

Oral solid dosage manufacturing companies, equipment and market

Next Article

Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Most clinical trials run in Canada failed to take basic steps toward transparency, analysis finds

STAT+: Most clinical trials run in Canada failed to tak...

Nov 27, 2023

Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines

Drugmakers push back on a clever tactic employers use t...

Mar 22, 2023

STAT+: FDA seeks to regulate lab-developed tests, closing the ‘Theranos loophole’

STAT+: FDA seeks to regulate lab-developed tests, closi...

Sep 30, 2023